SCHEMBL1022607

SCHEMBL1022607

O=C(O)Cc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
TSHR P16473 1/20 0.57
CASP1 P29466 1/20 0.57
ALDH1A1 P00352 4/20 0.52
TP53 P04637 1/20 0.52
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
KEAP1 Q14145 1/20 0.50
NFE2L2 Q16236 1/20 0.50
DCLRE1B Q9H816 1/20 0.47
CXCL8 P10145 1/20 0.46
CYP2C9 P11712 1/20 0.46
CHRM1 P11229 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27780337 0.87 KEAP1 (0.49) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL29566 0.85 KEAP1 (0.47) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL2334381 0.85 ALDH1A1 (0.57) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL16632529 0.84 SMN1; SMN2 (0.52) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL8482266 0.82 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL8482265 0.82 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL1548854 0.82 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL16041940 0.82 KEAP1 (0.54) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL5500307 0.81 SMN1; SMN2 (0.53) SMN1; SMN2TSHRCASP1ALDH1A1TP53
Ethane SCHEMBL7194508 0.81 SMN1; SMN2 (0.57) SMN1; SMN2TSHRCASP1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110302733-B Preparation method of double-halogen nitrogen-containing heterocyclic compound 北京六合宁远科技有限公司 2021-07-30 CN claimed
CN-110302733-B Preparation method of double-halogen nitrogen-containing heterocyclic compound 北京六合宁远科技有限公司 2021-07-30 CN disclosed
CN-110302733-B Preparation method of double-halogen nitrogen-containing heterocyclic compound 北京六合宁远科技有限公司 2021-07-30 CN disclosed
CN-110302733-A Preparation method of double-halogen nitrogen-containing heterocyclic compound 北京六合宁远科技有限公司 2019-10-08 CN disclosed
US-8461107-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-06-11 US disclosed
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
CN-102014911-A HCV NS3 protease inhibitors MERCK & CO INC 2011-04-13 CN disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed
EP-2271345-A1 HCV NS3 PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2011-01-12 EP disclosed
US-4801593-A VIRICIDE FOR RHINITIS VIRUS CONTAINING 2-PHENYLTETRALIN DERIVATIVE BURROUGHS WELLCOME CO. (US) 1989-01-31 US disclosed
EP-0299663-A2 Antihistaminic aromatic tetrahydroazepinones (and thiones) A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1989-01-18 EP disclosed
US-4746657-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1988-05-24 US disclosed
EP-0025598-B1 THE USE OF 2-PHENYLTETRALIN DERIVATIVES, OR HETEROCYCLIC ANALOGUES, IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM THE WELLCOME FOUNDATION LIMITED (GB) 1984-08-01 EP disclosed
US-4335129-A ANALGESIC, ANTIINFLAMMATORY YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1982-06-15 US disclosed
US-4329455-A ANALGESICS, ANTIINFLAMMATORY AGENTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1982-05-11 US disclosed
EP-0025598-A1 The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them THE WELLCOME FOUNDATION LIMITED (GB) 1981-03-25 EP disclosed
US-4163844-A ANALGESICS, ANTIINFLAMMATORY AGENTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1979-08-07 US disclosed
US-4025505-A ANTICONVULSANTS CIBA-GEIGY CORPORATION (US) 1977-05-24 US disclosed
US-3998954-A 1,3(2H,4H)-Dioxoisoquinoline-4-carboxamides used as anti-inflammatory agents PFIZER INC. (US) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC SMN1; SMN2 4284/4885TSHR 4610/4885CASP1 179/4885
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 SMN1; SMN2 4405/4885TSHR 4780/4885CASP1 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.